New Key Statistics Module, Z-Score and F-Score
NAS:ALNY Key Ratios
| Market Cap $ M | 19,268.49 |
| Enterprise Value $ M | 18,198.44 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 9.71 |
| Price/Free Cash Flow | 169.82 |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 2,003.00 |
| EPS (TTM) $ | -2.68 |
| Beneish M-Score | -2.41 |
| 10-y EBITDA Growth Rate % | -7.60 |
| 5-y EBITDA Growth Rate % | 19.50 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -92.27 |
| EV-to-EBITDA | -180.57 |
| PEG | -- |
| Shares Outstanding M | 126.49 |
| Net Margin (%) | -16.58 |
| Operating Margin % | -8.78 |
| Pre-tax Margin (%) | -16.21 |
| Quick Ratio | 3.07 |
| Current Ratio | 3.17 |
| ROA % (ttm) | -9.08 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -17.46 |
| Dividend Yield % | -- |
| Altman Z-Score | 1.26 |
ALNY Number of Guru Trades
ALNY Volume of Guru Trades
Gurus Latest Trades with NAS:ALNY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ALNY is held by these investors
Total 4
Alnylam Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:ALNY
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers